Cargando…

COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis

Up‐to‐date information on coronavirus disease 2019 (COVID‐19) outcomes and risk factors in haematopoietic cell transplantation (HCT) recipients is required to inform on decisions about cancer treatment and COVID‐19 mitigation strategies. We performed a meta‐analysis to address this knowledge gap. Al...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Yeong Jer, Khan, Umair, Karpha, Indrani, Ross, Andrew, Saif, Muhammad, Remberger, Mats, Kalakonda, Nagesh, Pettitt, Andrew R., Floisand, Yngvar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350043/
https://www.ncbi.nlm.nih.gov/pubmed/35941880
http://dx.doi.org/10.1002/jha2.465
_version_ 1784762174992809984
author Lim, Yeong Jer
Khan, Umair
Karpha, Indrani
Ross, Andrew
Saif, Muhammad
Remberger, Mats
Kalakonda, Nagesh
Pettitt, Andrew R.
Floisand, Yngvar
author_facet Lim, Yeong Jer
Khan, Umair
Karpha, Indrani
Ross, Andrew
Saif, Muhammad
Remberger, Mats
Kalakonda, Nagesh
Pettitt, Andrew R.
Floisand, Yngvar
author_sort Lim, Yeong Jer
collection PubMed
description Up‐to‐date information on coronavirus disease 2019 (COVID‐19) outcomes and risk factors in haematopoietic cell transplantation (HCT) recipients is required to inform on decisions about cancer treatment and COVID‐19 mitigation strategies. We performed a meta‐analysis to address this knowledge gap. All studies with at least five patients who reported COVID‐19‐related deaths in HCT recipients were included. The primary outcome was COVID‐19‐related death. Secondary outcomes were COVID‐19‐related mechanical ventilation (MV) and intensive care unit (ITU) admission. The cumulative COVID‐19‐related death rate among HCT recipients was 21% (95% confidence interval [CI] 18%–24%), while MV and ITU admission rates were 14% (95% CI 11%–17%) and 18% (95% CI 14%–22%), respectively. Subgroup analysis showed higher death rates in patients who developed COVID‐19 within 12 months of HCT (risk ratio [RR] 1.82, 95% CI 1.09–3.03), within 6 months of receiving immunosuppressant drugs (RR 2.11, 95% CI 1.38–3.20) or in the context of active graft‐versus‐host disease (RR 2.38, 95% CI 1.10–5.16). Our findings support the idea that HCT should remain an integral part of cancer treatment during the COVID‐19 pandemic but also highlight the need to prioritise preventative measures in those patients who are at increased risk of adverse COVID‐19 outcomes.
format Online
Article
Text
id pubmed-9350043
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93500432022-08-04 COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis Lim, Yeong Jer Khan, Umair Karpha, Indrani Ross, Andrew Saif, Muhammad Remberger, Mats Kalakonda, Nagesh Pettitt, Andrew R. Floisand, Yngvar EJHaem Cell Therapy/Stem Cell Transplantation Up‐to‐date information on coronavirus disease 2019 (COVID‐19) outcomes and risk factors in haematopoietic cell transplantation (HCT) recipients is required to inform on decisions about cancer treatment and COVID‐19 mitigation strategies. We performed a meta‐analysis to address this knowledge gap. All studies with at least five patients who reported COVID‐19‐related deaths in HCT recipients were included. The primary outcome was COVID‐19‐related death. Secondary outcomes were COVID‐19‐related mechanical ventilation (MV) and intensive care unit (ITU) admission. The cumulative COVID‐19‐related death rate among HCT recipients was 21% (95% confidence interval [CI] 18%–24%), while MV and ITU admission rates were 14% (95% CI 11%–17%) and 18% (95% CI 14%–22%), respectively. Subgroup analysis showed higher death rates in patients who developed COVID‐19 within 12 months of HCT (risk ratio [RR] 1.82, 95% CI 1.09–3.03), within 6 months of receiving immunosuppressant drugs (RR 2.11, 95% CI 1.38–3.20) or in the context of active graft‐versus‐host disease (RR 2.38, 95% CI 1.10–5.16). Our findings support the idea that HCT should remain an integral part of cancer treatment during the COVID‐19 pandemic but also highlight the need to prioritise preventative measures in those patients who are at increased risk of adverse COVID‐19 outcomes. John Wiley and Sons Inc. 2022-06-14 /pmc/articles/PMC9350043/ /pubmed/35941880 http://dx.doi.org/10.1002/jha2.465 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cell Therapy/Stem Cell Transplantation
Lim, Yeong Jer
Khan, Umair
Karpha, Indrani
Ross, Andrew
Saif, Muhammad
Remberger, Mats
Kalakonda, Nagesh
Pettitt, Andrew R.
Floisand, Yngvar
COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis
title COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis
title_full COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis
title_fullStr COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis
title_full_unstemmed COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis
title_short COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis
title_sort covid‐19 outcomes in haematopoietic cell transplant recipients: a systematic review and meta‐analysis
topic Cell Therapy/Stem Cell Transplantation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350043/
https://www.ncbi.nlm.nih.gov/pubmed/35941880
http://dx.doi.org/10.1002/jha2.465
work_keys_str_mv AT limyeongjer covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis
AT khanumair covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis
AT karphaindrani covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis
AT rossandrew covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis
AT saifmuhammad covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis
AT rembergermats covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis
AT kalakondanagesh covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis
AT pettittandrewr covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis
AT floisandyngvar covid19outcomesinhaematopoieticcelltransplantrecipientsasystematicreviewandmetaanalysis